Director Robert Glassman of Pharvaris N.V. (NASDAQ:PHVS) filed a Form 4 on September 11, 2026, disclosing a scheduled option exercise and sale of 8,000 common shares on September 9, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Transaction date: September 9, 2026, with 8,000 shares acquired via stock option exercise at $20.00 per share.
- Shares sold: 8,000 common shares disposed of at a weighted average price of $37.5495, with individual sale prices ranging from $37.21 to $37.83.
- 10b5-1 plan: The filing states the exercise and sale were a "scheduled exercise and sale from 10b5-1 trading plan."
- Resulting ownership: Following the transactions, Glassman directly holds 10,500 common shares.
- Option fully disposed: The exercised stock option, which had an exercise price of $20.00 and an expiration date of February 5, 2031, shows zero derivative securities remaining after the transaction.
- Vesting detail: According to the filing, 25% of the option vested on February 5, 2022, with the remaining shares vesting in 1/48 monthly installments thereafter.
Glassman's Cashless Option Exercise and Sale at Pharvaris N.V.
According to the Form 4 filed with the SEC, Robert Glassman, a director of Pharvaris N.V., executed a cashless option exercise transaction on September 9, 2026. The filing reports that Glassman exercised a stock option covering 8,000 shares of common stock at an exercise price of $20.00 per share, using transaction code "M" to reflect the acquisition of those shares. Simultaneously, all 8,000 shares were sold under transaction code "S."
The filing discloses that the 8,000 shares were sold at a weighted average price of $37.5495, representing multiple transactions on the same date. Individual sale prices ranged from $37.21 to $37.83. The filing notes that Glassman "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price." The stock option exercised carried an expiration date of February 5, 2031, and following the exercise, zero shares of that derivative security remain beneficially owned.
Before the reported transactions, the filing indicates Glassman held 18,500 shares of common stock directly. After the option exercise (adding 8,000 shares) and the subsequent sale (disposing of 8,000 shares), his direct beneficial ownership stands at 10,500 shares. The form was signed by Marnus Nel as attorney-in-fact for Robert Glassman and filed on September 11, 2026.
What Was Disclosed
The filing reported a same-day cashless exercise and sale of 8,000 Pharvaris N.V. common shares by director Robert Glassman on September 9, 2026, under a pre-established Rule 10b5-1 trading plan, leaving him with direct ownership of 10,500 shares.



Please wait processing your request...